12/15
08:19 am
hura
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone [Yahoo! Finance]
Medium
Report
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone [Yahoo! Finance]
12/15
07:50 am
hura
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
High
Report
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
12/14
01:26 am
hura
TuHURA Biosciences (NASDAQ:HURA) was downgraded by analysts at
Wall Stre
Medium
Report
TuHURA Biosciences (NASDAQ:HURA) was downgraded by analysts at
Wall Stre
12/11
07:50 am
hura
TuHURA Biosciences Provides Corporate Update Following Recent Financing [Yahoo! Finance]
Medium
Report
TuHURA Biosciences Provides Corporate Update Following Recent Financing [Yahoo! Finance]
12/11
07:30 am
hura
TuHURA Biosciences Provides Corporate Update Following Recent Financing
Low
Report
TuHURA Biosciences Provides Corporate Update Following Recent Financing
12/9
09:49 am
hura
TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering
High
Report
TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering
12/8
07:50 am
hura
TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
Neutral
Report
TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
11/18
06:19 am
hura
HURA: Third Quarter Results [Yahoo! Finance]
Medium
Report
HURA: Third Quarter Results [Yahoo! Finance]
11/17
07:56 am
hura
TuHURA Biosciences: Potential In Immunotherapy Resistance, But How Will It Be Funded? [Seeking Alpha]
High
Report
TuHURA Biosciences: Potential In Immunotherapy Resistance, But How Will It Be Funded? [Seeking Alpha]
11/14
02:39 pm
hura
TuHURA Biosciences (NASDAQ:HURA) had its price target lowered by analysts at Maxim Group from $15.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
TuHURA Biosciences (NASDAQ:HURA) had its price target lowered by analysts at Maxim Group from $15.00 to $8.00. They now have a "buy" rating on the stock.
11/14
07:16 am
hura
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Low
Report
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
11/14
07:00 am
hura
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Low
Report
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
11/3
09:01 am
hura
TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition
Medium
Report
TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition
10/25
12:13 pm
hura
TuHURA Biosciences (NASDAQ:HURA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
TuHURA Biosciences (NASDAQ:HURA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.